{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T11:51:39Z","timestamp":1773402699838,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ymgme.2019.07.003","type":"journal-article","created":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T06:12:21Z","timestamp":1562652741000},"page":"321-324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["High doses of biotin can interfere with immunoassays that use biotin-strept(avidin) technologies: Implications for individuals with biotin-responsive inherited metabolic disorders"],"prefix":"10.1016","volume":"127","author":[{"given":"Barry","family":"Wolf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2019.07.003_bb0005","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1177\/1352458516667568","article-title":"MS-SPI study group, MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: a randomised, double-blind, placebo-controlled study","volume":"22","author":"Tourbah","year":"2016","journal-title":"Mult.Scler."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.msard.2017.09.030","article-title":"High dose biotin as a treatment for progressive multiple sclerosis","volume":"18","author":"Birnhaum","year":"2017","journal-title":"Multiple Scerosis Related Disord."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0015","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/09546634.2017.1395799","article-title":"Biotin for the treatment of nail disease: what is the evidence?","volume":"29","author":"Lipner","year":"2018","journal-title":"J.Dermatol.Treatment"},{"key":"10.1016\/j.ymgme.2019.07.003_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2018.02.018","article-title":"Rethinking biotin therapy for hair, nail, and skin disorders","author":"Lipner","year":"2018","journal-title":"J.Am.Acad.Dermatol."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0025","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000462981","article-title":"A review of the use of biotin for hair loss","volume":"3","author":"Patel","year":"2017","journal-title":"Skin Appendage Disord."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clinbiochem.2018.12.007","article-title":"Strategies for mitigating risk posed by biotin interference on clinical immunoassays","volume":"65","author":"Gifford","year":"2019","journal-title":"Clin.Biochem."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0035","first-page":"634","article-title":"Biotin interference in immunoassays based on biotin-strept(avidin) chemistry: an emerging threat","volume":"37","author":"Luong","year":"2019","journal-title":"Biochem.Adv."},{"issue":"Pt 2","key":"10.1016\/j.ymgme.2019.07.003_bb0040","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/000456329603300214","article-title":"Interference by biotin therapy on measurement of TSH and FTA by enzyme immunoassay on Boehringer Mannheim ES700 analyser","volume":"33","author":"Henry","year":"1996","journal-title":"Ann.Clin.Biochem."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0045","doi-asserted-by":"crossref","first-page":"338","DOI":"10.5582\/ddt.2016.01074","article-title":"Biotin treatment causing erroneous immunoassay results: a word of caution for clinicians","volume":"10","author":"Suluiman","year":"2016","journal-title":"Drug Discov. Therapeut."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0050","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.5858\/arpa.2017-0107-LE","article-title":"Biotin interference in clinical immunoassays: a cause for concern","volume":"141","author":"Holmes","year":"2017","journal-title":"Arch.Pathol.Lab.Med."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0055","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.clinbiochem.2019.01.004","article-title":"Further assessment of the prevalance of biotin supplementation and its impact on risk","volume":"65","author":"Trambas","year":"2019","journal-title":"Clin.Biochem."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0060","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMc1602096","article-title":"Biotin treatment micmicking Graves\u2019 disease","volume":"375","author":"Kummer","year":"2016","journal-title":"N.Engl.J.Med."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0065","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1177\/0004563219842231","article-title":"Biotin interference in immunoassay: a review for the laboratory scientist","volume":"56","author":"Avery","year":"2019","journal-title":"Ann.Clin.Biochem."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0070","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.cca.2018.10.013","article-title":"Comprehensive assaessment of biotin interference in immunoassays","volume":"487","author":"Li","year":"2018","journal-title":"Clin.Chim.Acta"},{"key":"10.1016\/j.ymgme.2019.07.003_bb0075","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11154-018-9453-4","article-title":"Approach to the interpretation of unexpected laboratory results arising in the care of patients with inborn errors of metabolism (IEM)","volume":"19","author":"Mattiman","year":"2017","journal-title":"Rev. Endocrine Metabol. Dis."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0080","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0009-8981(83)90096-7","article-title":"Biotinidase deficiency: the enzymatic defect in late-onset multiple carboxylase deficiency","volume":"131","author":"Wolf","year":"1983","journal-title":"Clin.Chim.Acta."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0085","series-title":"GeneReviews (Internet)","article-title":"Biotinidase deficiency","author":"Wolf","year":"2018"},{"key":"10.1016\/j.ymgme.2019.07.003_bb0090","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1172\/JCI110402","article-title":"Mutant holocarboxylase synthetase: evidence for the enzyme defect in early infantile biotin-responsive multiple carboxylase deficiency","volume":"68","author":"Burri","year":"1981","journal-title":"J.Clin.Invest."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0095","first-page":"590","article-title":"Evidence for a defect of holocarboxylase synthetase activity in cultured lymphoblasts from a patient with biotin-responsive multiple carboxylase deficiency","volume":"34","author":"Saunders","year":"1982","journal-title":"Am.J.Hum.Genet."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0100","series-title":"GeneReviews (Internet)","article-title":"Biotin-thiamine-responsive basal ganglia disease","author":"Tabarki","year":"2013"},{"key":"10.1016\/j.ymgme.2019.07.003_bb0105","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00439-016-1751-x","article-title":"Mutations in SLC5A6 associated with brain, immune, bone and intestinal dysfunction in a young child","volume":"136","author":"Subramanian","year":"2017","journal-title":"Hum.Genet."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0110","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pediatrneurol.2017.10.013","article-title":"Biotin and acetazolamide for treatment of an unusual chld with autism plus lack of nail and hair growth","volume":"79","author":"Duchowny","year":"2018","journal-title":"J.Pediatr.Neurol."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0115","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1542\/peds.68.1.113","article-title":"Multiple carboxylase deficiency: clinical and biochemical improvement following neonatal biotin treatment","volume":"68","author":"Wolf","year":"1981","journal-title":"Pediatr."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0120","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/gim.2016.135","article-title":"Successful outcomes of older adolescents and adults with profound biotinidase deficiency identified by newborn screening","volume":"19","author":"Wolf","year":"2016","journal-title":"Genet.Med."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0125","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3935","article-title":"Wolf disorders of biotin metabolism","author":"B","year":"2001"},{"key":"10.1016\/j.ymgme.2019.07.003_bb0130","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2010.01.003","article-title":"Clinical issues and frequent questions about biotinidase deficiency","volume":"100","author":"Wolf","year":"2013","journal-title":"Mol.Genet.Metab."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0135","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ejpn.2015.05.008","article-title":"Treatment of biotin-responsive basal ganglia disease: open comparative study between the combination of biotin plus thiamine versus thiamin alone","volume":"19","author":"Tabarki","year":"2015","journal-title":"Eur.J.Paediatr.Neurol."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0140","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000448034","article-title":"Biochemical hyperthyroidism in newborn baby caused by assay interaction from biotin intake","volume":"5","author":"Pedersen","year":"2016","journal-title":"Eur.Thyroid J."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0145","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1177\/1352458515596457","article-title":"Biotinidase deficiency mimicking neurmyelitis optica: initially exhibiting sympotms in adulthood","volume":"21","author":"Bottin","year":"2015","journal-title":"Mult.Scler."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0150","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/jnnp-2017-316644","article-title":"Adult-onset biotinidase deficiency: two individuals with severe, but reversible optic neuropathy","volume":"89","author":"Deschamps","year":"2018","journal-title":"J.Neurol.Neurosurg.Psychiatry"},{"key":"10.1016\/j.ymgme.2019.07.003_bb0155","first-page":"117","article-title":"Irreversibility of symptoms with biotin therapy in an adult with profound biotinidase deficiency","volume":"36","author":"Ferreira","year":"2017","journal-title":"J.Inherit.Metab.Dis."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0160","unstructured":"The FDA Warns that Biotin May Interfere with Lab Tests: FDA Safety Communication. https:\/\/www.fda.gov\/MedicalDevices\/Safety\/AlertsandNotices\/ucm5865.2017)."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0165","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/0004563217701777","article-title":"Characterization of the scope and magnitude of biotin interference in susceptible Roche Elecsys competitive and sandwich immunoassays","volume":"55","author":"Trambas","year":"2017","journal-title":"Ann.Clin.Biochem."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0170","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1515\/cclm-2017-0059","article-title":"A simple method to detect biotin interference on immunoassays","volume":"55","author":"Lam","year":"2017","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0175","doi-asserted-by":"crossref","first-page":"989","DOI":"10.4158\/EP171761.RA","article-title":"Biotin interference with routine clinical immunoassays: understand the causes and mitigate the risks","volume":"23","author":"Samarasinghe","year":"2017","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0180","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1177\/0004563217707783","article-title":"Depletion of biotin using streptavidin-coated microparticles: a validated solution to the problem of biotin interference in streptavidin-biotin immunoassays","volume":"55","author":"Trambas","year":"2017","journal-title":"Ann.Clin.Biochem."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0185","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1515\/cclm-2016-1183","article-title":"High-dose biotin therapy leading to false biochemical endocrine profiles: validation of a simple method to overcome biotin interference","volume":"55","author":"Piketty","year":"2017","journal-title":"Clin.Chem.Lab.Med."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0190","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5603\/EP.a2018.0084","article-title":"The effects of biotin interference on the results of blood hormone assays","volume":"70","author":"Ostrowska","year":"2018","journal-title":"Endokrynologia Polska"},{"key":"10.1016\/j.ymgme.2019.07.003_bb0195","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4155\/ipk-2017-0013","article-title":"Population pharmacokinetics of exogeneous biotin and the relationship between biotin serum levels and in vitro immunoassay interference","volume":"2","author":"Grimsey","year":"2017","journal-title":"Int.J.Pharmacokinet."},{"key":"10.1016\/j.ymgme.2019.07.003_bb0200","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1517\/17425255.2016.1136288","article-title":"Parmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treamtnet of progressive multiple sclerosis","volume":"12","author":"PeyroSaint Paul","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719219304056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719219304056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T08:15:18Z","timestamp":1663920918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719219304056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1096719219304056"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2019.07.003","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High doses of biotin can interfere with immunoassays that use biotin-strept(avidin) technologies: Implications for individuals with biotin-responsive inherited metabolic disorders","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2019.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}